DB
TCRT icon

Dmitry Balyasny’s Alaunos Therapeutics TCRT Stock Holding History

Dmitry Balyasny’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-205
Closed -$38K – 3254
2022
Q2 		$38K Buy
+205
New +$19.6K ﹤0.01% 2401
2016
Q3 		– Sell
-144
Closed -$119K – 1257
2016
Q2 		$119K Buy
+144
New +$157K ﹤0.01% 1087

Other funds holding TCRT

MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dmitry Balyasny's TCRT Position: Q3 2022 in Review

Dmitry Balyasny sold out of Alaunos Therapeutics (TCRT) in Q3 2022, closing a stake of 205 shares — an estimated $38K sold.

Dmitry Balyasny first reported a position in TCRT in Q2 2016 and held it in 2 quarters. The position peaked at $119K in Q2 2016. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

  • Dmitry Balyasny reported no remaining Alaunos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 205 Alaunos Therapeutics shares in Q3 2022, an estimated $38K.
  • Dmitry Balyasny first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 2 quarters.
  • Dmitry Balyasny's Alaunos Therapeutics position peaked at $119K in Q2 2016.
  • 125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.